CD18 Monoclonal Antibody (YFC118.3), Invitrogen™

Descripción

The epitope recognized by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. We recommend the use of acetone fixation for frozen sections. A suggested positive control for immunohistochemical applications is human tonsil. For FACS analysis, use 10 μL of the suggested working dilution to label 1x10^6 cells in 100 μL. Rat anti Human CD18 antibody, clone YFC118.3 was clustered at the Fourth International Workshop on Leucocyte Differentiation Antigen (code number N221) as recognizing the CD18 antigen.

CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.